Vimarsana
Biggest News Aggregation in the World

Bryan Riggsbee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bryan Riggsbee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bryan Riggsbee Today - Breaking & Trending Today

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors - Vimarsana News

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx Inc. announced that Bryan Riggsbee joins CareDx?s Board of Directors, effective March 11, 2024. Riggsbee previously served as Chief Financial Officer at Myriad Genetics, where he made...

🔒 CFOs are favouring equity over debt as banks hike interest rates - Vimarsana News

🔒 CFOs are favouring equity over debt as banks hike interest rates

In a notable shift, CFOs like Bryan Riggsbee of Myriad Genetics are opting for equity over debt as central banks hike interest rates.

Debt-addicted companies look to equity as interest costs skyrocket - Vimarsana News

Debt-addicted companies look to equity as interest costs skyrocket

For the first time in a long while, it’s cheaper for some companies in the U.S. to sell shares than to borrow in the debt markets. Read more

Myriad Genetics (NASDAQ:MYGN) Stock Price Up 2.7% - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Stock Price Up 2.7%

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) shares shot up 2.7% on Thursday . The company traded as high as $18.76 and last traded at $18.73. 139,980 shares were traded during mid-day trading, a decline of 73% from the average session volume of 523,469 shares. The stock had previously closed at $18.24. Wall Street […]

Myriad Genetics (NASDAQ:MYGN) Earns Neutral Rating from Analysts at Piper Sandler - Vimarsana News

Myriad Genetics (NASDAQ:MYGN) Earns Neutral Rating from Analysts at Piper Sandler

Piper Sandler initiated coverage on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a research note released on Thursday morning, Benzinga reports. The firm issued a neutral rating and a $23.00 price target on the stock. A number of other analysts have also weighed in on MYGN. StockNews.com upgraded shares of Myriad Genetics from […]